Inside Pfizer’s 3Q17 Estimates
A look at Pfizer
Pfizer (PFE) is one of the largest pharmaceutical companies worldwide by revenue and is set to release its 3Q17 earnings results on October 31, 2017. For 3Q17, Wall Street analysts estimate that Pfizer will report EPS (earnings per share) of $0.64 on revenues of $13.18 billion.
Interested in AGN? Don't miss the next report.
Receive e-mail alerts for new research on AGN
3Q17 revenue estimates
Analysts’ estimate Pfizer to report a growth of 1% in its 3Q17 revenues to $13.17 billion, compared with $13.04 billion for 3Q16. Revenues are expected to be driven by growth in overall sales for innovative health products including Eliquis, Ibrance, Lyrica, Xeljanz, and Xtandi. These sales could be partially offset by lower sales of essential health products including Celebrex, Lyrica, and Zyvox, and other legacy established products.
Revenues from legacy Hospira products are expected to fall during 3Q17.
Wall Street analysts estimate that Pfizer’s gross profit margin will rise 2.8% YoY (year-over-year) to 79.2% in 3Q17, compared with 76.4% in 3Q16. Its EBITDA (earnings before interest, tax, depreciation, and amortization) margin is expected to fall 1.2% YoY to 41.9% in 3Q17 due to increased research and development expenses, as well as increased selling, general, and administrative expenses in 3Q17.
Pfizer’s net adjusted income is expected to rise to $3.87 billion in 3Q17, compared with $3.73 billion in 3Q16.
Notably, the Health Care Select Sector SPDR ETF (XLV) holds 6.4% of its total assets in Pfizer (PFE). XLV also holds 5.6% of its assets in Merck (MRK), 3.5% in Gilead Sciences (GILD), and 2.6% in Allergan (AGN).